Patent application number | Description | Published |
20090291143 | Combination of Azelastine and Steroids - A pharmaceutical product or formulation, which comprises azelastine or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, and a steroid, or a pharmaceutical acceptable salt, solvate or physiologically functional derivative thereof, preferably the product or formulation being in a form suitable for nasal or ocular administration. | 11-26-2009 |
20090318397 | Combination of Azelastine and Steroids - A pharmaceutical product or formulation, which comprises azelastine or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, and a steroid, or a pharmaceutical acceptable salt, solvate or physiologically functional derivative thereof, preferably the product or formulation being in a form suitable for nasal or ocular administration. | 12-24-2009 |
20090320838 | DRY POWDER INHALER - An inhaler ( | 12-31-2009 |
20090325917 | Pharmaceutical Compositions and Nasal Spray Incorporating Anhydrous Mometasone Furoate - A stable aqueous pharmaceutical composition comprising anhydrous mometasone furoate and a pharmaceutically acceptable carrier. | 12-31-2009 |
20100063016 | Pharmaceutical Combinations - A pharmaceutical combination comprising (a) a combination of two or more bronchodilators; or (b) a combination of at least one bronchodilator in combination with at least one corticosteroid. | 03-11-2010 |
20100204195 | Pharmaceutical Compositions and Process for Making Them - Amorphous HMG CoA reductase inhibitors, especially amorphous atorvastatin, are described. Also described are pharmaceutical combinations comprising amorphous HMG CoA reductase inhibitors in combination with cholesterol absorption inhibitors or fibrates. A method of manufacturing the compositions using a hot melt extrusion process are also described. | 08-12-2010 |
20100285115 | Novel Antiretroviral Combination - The invention relates to pharmaceutical compositions containing a combination of atazanavir and ritonavir, to methods of making them, and their use in medicine. | 11-11-2010 |
20100331289 | Combination of Azelastine and Steroids - A pharmaceutical product or formulation, which comprises azelastine or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, and a steroid, or a pharmaceutical acceptable salt, solvate or physiologically functional derivative thereof, preferably the product or formulation being in a form suitable for nasal or ocular administration. | 12-30-2010 |
20110008412 | Oral Formulations for 5-HT-Receptor Agonists, Uses and Methods of Treatment Employing The Same - A pharmaceutically acceptable oral formulation comprising core material which comprises a therapeutically effective amount of a 5-HT-receptor agonist, or a pharmaceutically acceptable salt, solvate or derivative thereof, which core material is provided with a substantially water resistant coating comprising one or more substantially water resistant materials. | 01-13-2011 |
20110008429 | Anti-Retroviral Combination - A pharmaceutical composition comprising a solid unit dosage form comprising:
| 01-13-2011 |
20110028456 | Solid Pharmaceutical Dosage Form - A pharmaceutical composition comprising a solid unit dosage form comprising: one or more of pharmaceutically active ingredients selected from valacyclovir, olanzapine, voriconazole, topotecan, artesunate, amodiaquine, guggulosterone, ramipril, telmisartan, tibolone, atorvastatin, simvastatin, amlodipine, ezetimibe, fenofibrate, tacrolimus, valgancyclovir, valsartan, clopidrogel, estradiol, trenbolone, efavirenz, metformin, pseudoephedrine, verapamil, felodipine, valproic acid/sodium valproate, mesalamine, hydrochlorothiazide, levosulpiride, nelfinavir, cefixime and cefpodoxime proxetil in combination with a water insoluble polymer and/or a water soluble polymer. Methods for making the pharmaceutical composition are also disclosed. | 02-03-2011 |
20110104262 | Topical Combinations Comprising an Antimycotic Agent and an Antiviral Agent - There is provided a pharmaceutical composition comprising an antimycotic agent and an antiviral agent, useful for prophylaxis and/or treatment of an associated infection and/or disease and a method of manufacturing thereof. | 05-05-2011 |
20130029951 | Combination of Azelastine and Ciclesonide for Nasal Administration - A pharmaceutical product or formulation, which comprises azelastine or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, and a steroid, or a pharmaceutical acceptable salt, solvate or physiologically functional derivative thereof, preferably the product or formulation being in a form suitable for nasal or ocular administration. | 01-31-2013 |
20130029952 | Combination of Azelastine and Mometasone for Nasal Administration - A pharmaceutical product or formulation, which comprises azelastine or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, and a steroid, or a pharmaceutical acceptable salt, solvate or physiologically functional derivative thereof, preferably the product or formulation being in a form suitable for nasal or ocular administration. | 01-31-2013 |
20130065930 | TOPICAL COMPOSITION - A topical composition comprising: fipronil or a pharmaceutically acceptable salt thereof; at least one surfactant and at least one crystallization inhibitor for the treatment and protection of animals which are infested with parasites. | 03-14-2013 |
20130074834 | Pharmaceutical Combinations - A pharmaceutical combination comprising (a) a combination of two or more bronchodilators; or (b) a combination of at least one bronchodilator in combination with at least one corticosteroid. | 03-28-2013 |
20130160761 | Pharmaceutical Aerosol Composition - A pharmaceutical aerosol composition comprising at least one hydrofluoroalkane propellant; at least one active agent complexed with an adjuvant; and, optionally, at least one pharmaceutically acceptable excipient. | 06-27-2013 |
20130202654 | Topical Foam Composition - A topical foam pharmaceutical composition for rectal administration comprising rifaximin in the form of nanosized particles is described. Also described is a method of making the composition and the use of the composition to as a medicament. | 08-08-2013 |
20130274232 | Pharmaceutical Compositions - A pharmaceutical composition for inhalation comprising R(+) budesonide and one bronchodilators, and, optionally, one or more pharmaceutically acceptable excipients. | 10-17-2013 |
20130295023 | Inhalation Solutions - A inhaler for an inhalation formulation, comprising a canister containing a pharmaceutical composition under pressure; a metering valve for measuring a metered dose of the composition from the canister for administration to a patient in need thereof; and an actuator for actuating discharge of the metered dose to the patient; wherein the actuator includes a discharge orifice having a diameter in the range 0.2 to 0.4 mm; and wherein the pharmaceutical composition comprises an anticholinergic agent and a pharmaceutically acceptable propellant. | 11-07-2013 |
20130302415 | Pharmaceutical Composition - A pharmaceutical composition comprising efavirenz wherein the efavirenz is in the form of nanoparticles is disclosed. | 11-14-2013 |
20130315998 | Topical Foam Composition - A topical foam pharmaceutical composition for rectal administration comprising rifaximin is described. Also described is a method of making the composition and the use of the composition as a medicament. | 11-28-2013 |
20130330281 | Pharmaceutical Compositions - A pharmaceutical composition for inhalation comprising R (+) budesonide and one or more bronchodilators, and, optionally, one or more pharmaceutically acceptable excipients is described. | 12-12-2013 |
20140024693 | TOPICAL COMPOSITION - A topical composition comprising: fipronil or a pharmaceutically acceptable salt thereof; at least one surfactant and at least one crystallization inhibitor for the treatment and protection of animals which are infested with parasites. | 01-23-2014 |
20150072010 | Combination of Azelastine and Mometasone for Nasal Administration - A pharmaceutical product or formulation, which comprises azelastine or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, and a steroid, or a pharmaceutical acceptable salt, solvate or physiologically functional derivative thereof, preferably the product or formulation being in a form suitable for nasal or ocular administration. | 03-12-2015 |